How has BridgeBio Pharma's software and technology licenses, net changed year-over-year?

BridgeBio Pharma's software and technology licenses, net increased by 12.1% year-over-year, from $16.61M to $18.62M.

What is the long-term trend for BridgeBio Pharma's software and technology licenses, net?

Over 5 years (2020 to 2025), BridgeBio Pharma's software and technology licenses, net has grown at a -6.9% compound annual growth rate (CAGR), from $23.93M to $16.71M.

BridgeBio Pharma BBIO Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

PfizerPFE

——

Ionis PharmaceuticalsIONS

——

BioMarin PharmaceuticalsBMRN

——

ALN

Alnylam PharmaceuticalsALNY

——

Revolution Medicines, Inc.RVMD

——

Roivant SciencesROIV

——

Other financials

Income statement

See full

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

See full

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

See full

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

See full

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

See full

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BridgeBio Pharma's software and technology licenses, net?: BridgeBio Pharma (BBIO) reported software and technology licenses, net of $18.62M in Q1 2026.
How has BridgeBio Pharma's software and technology licenses, net changed year-over-year?: BridgeBio Pharma's software and technology licenses, net increased by 12.1% year-over-year, from $16.61M to $18.62M.
What is the long-term trend for BridgeBio Pharma's software and technology licenses, net?: Over 5 years (2020 to 2025), BridgeBio Pharma's software and technology licenses, net has grown at a -6.9% compound annual growth rate (CAGR), from $23.93M to $16.71M.